Actovegin, 40 mg/ml 5 ml 5 pcs

Pharmacotherapeutic group:

Tissue regeneration stimulator

ATC code:

B06AB

Pharmacological action

Pharmacodynamics

Antihypoxant. Actovegin® is a hemoderivative which is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 daltons pass through).

Positive effects on glucose transport and utilization, stimulates oxygen consumption (which leads to stabilization of plasma cell membranes during ischemia and reduction of lactate formation) thus possessing an anti-hypoxic effect, which starts manifesting itself 30 minutes after parenteral administration at the latest and reaches a maximum in 3 hours (2-6h) on average. Aktovegin® increases concentrations of adenosine triphosphate, adenosine diphosphate, phosphocreatine as well as amino acids – glutamate, aspartate and gamma-aminobutyric acid.

The effects of Actovegin® on oxygen uptake and utilization as well as insulin-like activity with stimulation of glucose transport and oxidation are significant in the treatment of diabetic polyneuropathy (DPN). In patients with diabetes mellitus and diabetic polyneuropathy Actovegin® reliably decreases symptoms of polyneuropathy (stabbing pain, burning sensation, parasthesias, numbness in lower extremities).

Pharmacokinetics

Pharmacokinetic methods cannot be used to study the pharmacokinetics of Actovegin® because it consists only of physiological components that are normally present in the body.

To date no decrease in the pharmacological effect of hemoderivatives has been found in patients with altered pharmacokinetics (e.g., hepatic or renal insufficiency, metabolic changes associated with advanced age, and metabolic features in newborns)

Indications

Metabolic and vascular disorders of the brain (including ischemic stroke and traumatic brain injury).
Peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers); diabetic polyneuropathy
Wound healing (ulcers of various etiologies, burns, trophic disorders (bedsores), disruption of wound healing processes).
Prevention and treatment of radiation injuries of the skin and mucous membranes during radiation therapy

Pharmacological effect

Pharmacotherapeutic group:

tissue regeneration stimulator

ATX code:

В06AB

Pharmacological action

Pharmacodynamics

Antihypoxant. Actovegin® is a hemoderivative, which is obtained through dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 daltons pass through).

It has a positive effect on the transport and utilization of glucose, stimulates oxygen consumption (which leads to the stabilization of plasma membranes of cells during ischemia and a decrease in the formation of lactate), thus possessing an antihypoxic effect, which begins to manifest itself no later than 30 minutes after parenteral administration and reaches a maximum after an average of 3 hours (2-6 hours). Actovegin® increases the concentrations of adenosine triphosphate, adenosine diphosphate, phosphocreatine, as well as amino acids – glutamate, aspartate and gamma-aminobutyric acid.

The effect of Actovegin® on the absorption and utilization of oxygen, as well as insulin-like activity with stimulation of glucose transport and oxidation are significant in the treatment of diabetic polyneuropathy (DPN). In patients with diabetes mellitus and diabetic polyneuropathy, Actovegin® significantly reduces the symptoms of polyneuropathy (stabbing pain, burning sensation, parasthesia, numbness in the lower extremities). Sensitivity disorders are objectively reduced, and the mental well-being of patients improves.

Pharmacokinetics

Using pharmacokinetic methods, it is impossible to study the pharmacokinetic parameters of the drug Actovegin®, since it consists only of physiological components that are usually present in the body.

To date, no decrease in the pharmacological effect of hemoderivatives has been found in patients with altered pharmacokinetics (for example, hepatic or renal failure, metabolic changes associated with old age, as well as metabolic characteristics in newborns)

Special instructions

With repeated administrations of the solution for infusion, the water-electrolyte balance of the blood plasma should be monitored.

The infusion solution and solution for injection have a slightly yellowish tint. The color intensity may vary from one batch to another depending on the characteristics of the starting materials used, but this does not adversely affect the activity of the drug or its tolerability.

Do not use a solution that is opaque or contains foreign particles. After opening the bottle (ampoule), the solution cannot be stored.

In the case of intramuscular administration, the drug is administered slowly, no more than 5 ml. Due to the possibility of an anaphylactic reaction, a test injection (2 ml IM) is recommended.

Active ingredient

Deproteinized hemoderivative of calf blood

Composition

1 ampoule contains:

active ingredient:

Actovegin® concentrate (in terms of dry deproteinized hemoderivative of calf blood)1) – 200.0 mg;

excipient:

water for injection – up to 5 ml.

Pregnancy

Use of the drug in pregnant women did not cause negative effects on the mother or fetus.

However, when used in pregnant women, the potential risk to the fetus must be taken into account.

Contraindications

hypersensitivity to the drug Actovegin® or similar drugs.
decompensated heart failure;
pulmonary edema;
oliguria;
anuria;
fluid retention in the body.

Side Effects

Allergic reactions:

skin rash;
skin hyperemia;
hyperthermia, up to anaphylactic shock.

Interaction

Currently unknown.

However, in order to avoid possible pharmaceutical incompatibility, it is not recommended to add other drugs to the Actovegin® infusion solution.

Storage conditions

In a place protected from light, at a temperature of 18–25 °C

Manufacturer

Takeda Pharmaceuticals LLC, Russia